![](https://reachora-public-videos.imgix.net/v/132/7/e/b187f6-ff76-4c22-95aa-2775e04e8a00/thumbnails/image_0.jpg)
![](https://reachora-public-thumbnails.imgix.net/uploaded/production/95c3eb03-f125-4637-b9ee-5b303fcc7bfc.jpg)
![](https://reachora-public-videos.imgix.net/v/132/4/d/9641d6-f7bd-46a1-9a0e-b27fbf2672b9/thumbnails/image_1.jpg)
![](https://reachora-public-videos.imgix.net/v/2/d/7/4f69f0-a584-459b-a5c6-b549ccaded3f/thumbnails/image_2.jpg)
![](https://reachora-public-thumbnails.imgix.net/uploaded/production/a79d3983-a816-4de4-b926-c3be326f130d.jpg)
![](https://reachora-public-videos.imgix.net/v/115/d/c/d3154c-6787-474a-8f61-6b50da82d468/thumbnails/image_1.jpg)
- Cardiology
- Rhythm Control, Atrial Fibrillation Surgery: Techniques and Technology
- Rhythm Control, Antiarrhythmic Drugs
- Rhythm Control, Antiarrhythmic Drugs: Outcomes and Complications
Pharmacological Long-term Rhythm Control
Atrial fibrillation (AF) is an exceedingly common arrhythmia. The management of this condition is largely based on pharmacotherapy, cardioversion, ablation, and devices. This 6-part course covers...
Atrial fibrillation (AF) is an exceedingly common arrhythmia. The management of this condition is largely based on pharmacotherapy, cardioversion, ablation, and devices. This 6-part course covers all pharmacotherapeutic aspects that arise in the context of AF. Co-morbidities are highly prevalent in AF patients and need to be considered in when therapeutic options are weighed against each other. At the end of the course, the physician will be up to date on all above aspects and confident in correctly applying the broad spectrum of pharmacologic approaches in AF.
This activity is funded by Bayer AG and is not intended for a UK audience